Biotex, Inc. published a blog breaking down the Safer Technologies Program, including its benefits, eligibility criteria, and what it could mean for a medical device's path to market.
Public source
Publisher name
Public post
Could your medical device qualify for the FDA’s Safer Technologies Program? Our latest blog breaks down the STeP program, including its benefits, eligibility criteria, a…
Company
Biotex, Inc.
- Industry
- Medical Device
- Location
- Houston, US
- Company size
- 51–200 employees
About Biotex, Inc.
Biotex specializes in the development, launch, and manufacturing of medical and bio-technologies. We partner with entrepreneurs, start-ups, and established companies to bring concepts to life with our full spectrum of medical device development and manufacturing. Biotex is a registered FDA manufacturer and has developed products from concept to FDA 510(k) cleared medical devices. BioTex maintains a pipeline of novel medical technologies at various stages of development. Biotex is committed to innovating and developing novel solutions to medical, biomedical, and bio-technology problems. Our current research programs focus on early stage development of both diagnostic and therapeutic medical devices.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
RQMIS (Regulatory/Quality Management Information Source)
RQMIS (Regulatory/Quality Management Information Source) published a blog breaking down the new FDA FY 2027 Medical Device User Fees and how companies can prepare for their U.S. regulatory pathway.
Research & Knowledge
Elevaris Medical Devices
Elevaris Medical Devices published a blog post detailing its approach to identifying risk, optimizing manufacturability, and accelerating commercialization.
Research & Knowledge
QRA Medical
QRA Medical published the MDR The MedTech Founder's Regulatory Playbook, which includes expert section on the decision-making unit and regulatory obligations for buyers.
Research & Knowledge
Gardner Law
Gardner Law published an alert examining CMS's proposed Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway and what medical device companies should consider before their clinical-development strategy is fixed.
Research & Knowledge
Boyd Biomedical